{"id":6777,"date":"2026-05-11T12:28:20","date_gmt":"2026-05-11T10:28:20","guid":{"rendered":"https:\/\/mediconomics.com\/glossar\/multivariate-analysis\/"},"modified":"2026-05-11T12:28:20","modified_gmt":"2026-05-11T10:28:20","slug":"multivariate-analysis","status":"publish","type":"glossary","link":"https:\/\/mediconomics.com\/en\/glossar\/multivariate-analysis\/","title":{"rendered":"Multivariate Analysis"},"content":{"rendered":"<p>Multivariate analysis in clinical research and biostatistics refers to statistical methods that simultaneously consider multiple dependent or independent variables. Unlike univariate methods, which analyze only one variable at a time, multivariate analysis allows for the simultaneous examination of relationships between multiple variables and enables statistical control of confounding variables (confounders). In the evaluation of clinical trials, multivariate analysis is indispensable for making valid statements about the effect of a treatment while accounting for relevant covariates. Without multivariate adjustment, treatment effects can be substantially over- or underestimated if prognostically relevant factors are unequally distributed between study groups.   <\/p>\n<h2>Key Multivariate Methods in Clinical Research<\/h2>\n<p>Depending on study design, endpoint type, and scientific question, various multivariate methods are employed:<\/p>\n<ul>\n<li><strong>Multiple linear regression:<\/strong> Examines the influence of multiple continuous or categorical predictors on a continuous endpoint. Frequently used for adjustment for baseline characteristics such as age, sex, or disease severity. <\/li>\n<li><strong>Logistic regression:<\/strong> Analyzes binary endpoints (e.g., responder vs. non-responder, event occurred vs. not occurred) while accounting for multiple covariates. Provides the odds ratio with confidence interval as the effect measure. <\/li>\n<li><strong>Cox proportional hazards model:<\/strong> Multivariate model for survival time data. Enables estimation of the hazard ratio while simultaneously controlling for confounders and is standard in oncological and cardiological registration trials where time to event is defined as the primary endpoint. <\/li>\n<li><strong>Multivariate analysis of variance (MANOVA):<\/strong> Simultaneously tests group differences for multiple dependent variables while controlling type I error inflation compared to multiple univariate tests.<\/li>\n<li><strong>Mixed Models for Repeated Measures (MMRM):<\/strong> Multivariate model for longitudinal data with repeated measurements. Accounts for the correlation structure within patients and is considered the preferred analysis method for continuous endpoints in psychiatric and neurological studies. MMRM uses all available data without explicit imputation and is statistically valid under the MAR assumption.  <\/li>\n<\/ul>\n<h2>Confounder Control and Adjustment<\/h2>\n<p>A central purpose of multivariate analyses in clinical trials is the control of confounding variables that are associated with both treatment assignment and the endpoint. In randomized controlled trials, confounders are balanced in expectation through randomization; however, multivariate adjustment for pre-specified prognostic factors can still improve the precision of the estimate and increase statistical power. In observational studies, multivariate adjustment is the primary tool for confounder control, as no randomization takes place. The covariates for which adjustment is performed must be specified in advance in the Statistical Analysis Plan to avoid selection bias. Post-hoc selection of covariates based on their statistical significance (data-driven selection) is not acceptable from a regulatory perspective and can lead to biased results.    <\/p>\n<h2>Regulatory Requirements<\/h2>\n<p>The EMA and ICH require in Guideline E9 (Statistical Principles for Clinical Trials) the pre-planned specification of the primary analysis model including all covariates. Post-hoc changes to the multivariate model\u2014such as the post-hoc addition of covariates\u2014are considered potentially results-driven and are critically evaluated. The ICH E9(R1) addendum further requires that multivariate analyses be consistent with the estimand definition of the study and that the choice of covariates be coherent with the underlying scientific question. For benefit assessment under Section 35a SGB V, the G-BA expects that multivariate adjustments for prognostic factors be transparently justified, documented in advance in the Statistical Analysis Plan, and conducted in a reproducible manner.   <\/p>\n<h2>Relevance for clinical trials<\/h2>\n<p>Multivariate analyses are now standard in the primary and exploratory evaluation of clinical trials. They enable more precise estimation of the treatment effect while accounting for patient-specific differences, thereby better representing the clinical relevance of the results. Full-service CROs such as mediconomics support sponsors in statistical model planning, specification of multivariate analyses in the Statistical Analysis Plan, and regulatory-compliant reporting in the Clinical Study Report. Careful model specification is critical to meet the requirements of both regulatory authorities and reimbursement agencies.   <\/p>\n<h2>Frequently Asked Questions (FAQ)<\/h2>\n<p><strong>When should a multivariate analysis be used instead of a univariate analysis?<\/strong><\/p>\n<p>A multivariate analysis is indicated when known or suspected confounders could influence the relationship between treatment and endpoint, when multiple endpoints are to be evaluated simultaneously, or when the precision of the effect estimate can be improved by adjustment for baseline covariates. In randomized trials, adjustment for stratification factors is recommended from a regulatory perspective. <\/p>\n<p><strong>How many covariates can be included in a multivariate model?<\/strong><\/p>\n<p>As a rule of thumb: at least 10\u201315 events (for survival time analyses) or observations (for regression models) should be available per covariate. Too many covariates relative to sample size leads to overfitting and unstable estimates. The selection of covariates should be substantively justified and specified in advance in the Statistical Analysis Plan.  <\/p>\n<p><strong>What is the difference between adjustment and matching?<\/strong><\/p>\n<p>In multivariate adjustment, confounders are statistically controlled in the regression model. In matching, study participants are grouped based on their confounder values so that treatment and control groups are comparable. Both approaches have advantages and disadvantages; propensity score methods combine both approaches and are widely used in observational studies and real-world evidence studies, as they enable flexible and transparent confounder control.  <\/p>\n<h2>Regulatory References<\/h2>\n<ul>\n<li>ICH E9 \u2013 Statistical Principles for Clinical Trials (1998): multivariate analysis methods, covariate adjustment<\/li>\n<li>ICH E9(R1) \u2013 Addendum on Estimands and Sensitivity Analysis (2019): consistency of models with estimands<\/li>\n<li>EMA Guideline on Adjustment for Baseline Covariates in Clinical Trials (EMA\/CHMP\/295050\/2013)<\/li>\n<li>EU Regulation No. 536\/2014 (CTR): requirements for pre-planned statistical analyses<\/li>\n<li>G-BA Rules of Procedure Section 35a SGB V: transparency and reproducibility of statistical adjustments<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Multivariate analysis in clinical research and biostatistics refers to statistical methods that simultaneously consider multiple dependent or independent variables. Unlike univariate methods, which analyze only one variable at a time, multivariate analysis allows for the simultaneous examination of relationships between multiple variables and enables statistical control of confounding variables (confounders). In the evaluation of clinical [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6777","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6777\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6777"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}